NASDAQ
TTRX
Last Price
US $7.12
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Turn Therapeutics Inc. cash flow to debt ratio of -3.19K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Turn Therapeutics Inc.'s free cash flow has decreased 85.92% from $-1.46M last year to $-2.72M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Turn Therapeutics Inc.'s debt to equity ratio is 0.98, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
Turn Therapeutics Inc.'s debt has increased relative to shareholder equity from -0.68 last year to 0.98 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Turn Therapeutics Inc. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Turn Therapeutics Inc. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Turn Therapeutics Inc. has insufficient data to evaluate this check.
Financial risk - Short term assets vs short term liabilities.
Turn Therapeutics Inc.'s short-term liabilities of $6.00M exceed its short-term assets of $5.20M, signaling financial risk
Decreasing performance - ROA.
Turn Therapeutics Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Turn Therapeutics Inc.'s return on equity of -116.83%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Turn Therapeutics Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Turn Therapeutics Inc. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Turn Therapeutics Inc. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Turn Therapeutics Inc. has negative free cash flow, indicating cash burn
Decreasing performance - Healthy earnings growth.
Turn Therapeutics Inc.'s yearly earnings has decreased 80.62% since last year from $-1.77M to $-3.19M, signaling decreasing performance
Increasing performance - Healthy revenue growth.
Turn Therapeutics Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Decreasing performance - ROIC.
ROIC -49.55% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.
Decreasing performance - 3-year revenue CAGR.
Turn Therapeutics Inc. has insufficient revenue history to calculate 3-year revenue CAGR.
Decreasing performance - Revenue consistency.
Turn Therapeutics Inc. had revenue growth in only 2.00 out of 5 years, indicating inconsistent revenue performance
Decreasing performance - ROE consistency.
Turn Therapeutics Inc. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Turn Therapeutics Inc. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Turn Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Turn Therapeutics Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Turn Therapeutics Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Turn Therapeutics Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - P/B ratio.
Turn Therapeutics Inc. has a price-to-book ratio of 33.39x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value
Overvalued - P/S ratio.
Turn Therapeutics Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-116.83%
Return on equity
ROIC: -49.55%
Valuation History
-38.1X
Price to Earnings
EV/EBITDA: -53.0X
Cash flow
Profit margin
-
(FY vs FY)
Cash flow Y/Y
-
(FY vs FY)
Fair Value
Market $7.12
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.